Dental Pain Relief: New Compound Enters Phase 2 Trials

DeltaRecently, Adolor Corporation announced the initiation of a Phase 2 study of ADL5859, a novel delta opioid agonist in development for the treatment of dental, as well as, other pain. The current study of ADL5859 is a randomized, double-blind, single-dose, active and placebo controlled parallel group study of ADL5859 for the treatment of pain after surgical removal of impacted third molars. The study is expected to enroll approximately 200 subjects. The active control is ibuprofen.

Through a proprietary research platform based on cloned, human opiod receptors, Adolor has identified a series of novel, orally active delta agonists that selectively stimulate the delta opioid receptor. The delta receptor is one of three opioid receptors that modulate pain; the other receptors being the mu and kappa receptors. Today, all marketed opioid drugs interact with the mu receptors in the brain and spinal cord. Delta compounds, like those being tested by Adolor, may contain analgesic properties comparable to mu opioid agonists, while limiting some of their well-known and problematic side effects.

For more information on this interesting compound, see: http://www.adolor.com/delta_agonist.html

Print this page Print This Post

Filed Under Surgery, Anesthesia 

Comments

Got something to say?